ORGO Organogenesis Holdings Inc.

Nasdaq organogenesis.com


$ 4.46 $ -0.06 (-1.39 %)    

Thursday, 06-Nov-2025 19:14:07 EST
QQQ $ 613.70 $ -9.99 (-1.61 %)
DIA $ 470.28 $ -2.78 (-0.59 %)
SPY $ 672.06 $ -6.30 (-0.93 %)
TLT $ 89.68 $ 0.21 (0.23 %)
GLD $ 367.25 $ -1.11 (-0.3 %)
$ 3.89
$ 3.95
$ 4.55 x 235
$ 4.60 x 15
$ 3.84 - $ 4.04
$ 2.61 - $ 6.71
566,719
na
493.69M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-09-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-12-2017 03-31-2017 10-Q
36 03-28-2017 12-31-2016 10-K
37 11-18-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 correction-organogenesis-hldgs-q3-adj-eps-018-beats-006-estimate-sales-150864m-beat-134100m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $...

 organogenesis-holdings-raises-fy2025-net-product-revenue-guidance-from-480000m-510000m-to-500000m-525000m

Organogenesis Holdings (NASDAQ:ORGO) raises FY2025 Net product revenue outlook from $480.000 million-$510.000 million to $500.0...

 organogenesis-hldgs-q3-adj-eps-018-beats-006-estimate-sales-150587m-beat-134100m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $...

 why-is-organogenesis-stock-trading-lower-friday

Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial ...

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 btig-reiterates-buy-on-organogenesis-holdings-maintains-7-price-target

BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ: ORGO) with a Buy and maintains $7 price target.

Core News & Articles

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

 organogenesis-announces-that-the-second-phase-3-randomized-controlled-trial-of-renu-did-not-achieve-statistical-significance-for-its-primary-endpoint-despite-the-renu-results-demonstrating-a-numerical-improvement-in-baseline-pain-reduction-over-the-first-phase-3-trial

CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc.

 cantor-fitzgerald-maintains-overweight-on-organogenesis-holdings-raises-price-target-to-9

Cantor Fitzgerald analyst Ross Osborn maintains Organogenesis Holdings (NASDAQ:ORGO) with a Overweight and raises the price ...

 organogenesis-holdings-narrows-fy2025-sales-guidance-from-48000m-53500m-to-48000m-51000m-vs-47780m-est

Organogenesis Holdings (NASDAQ:ORGO) narrows FY2025 sales outlook from $480.00 million-$535.00 million to $480.00 million-$510....

 organogenesis-hldgs-q2-adj-eps-006-misses-005-estimate-sales-10078m-miss-10117m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of...

 cantor-fitzgerald-reiterates-overweight-on-organogenesis-holdings-maintains-7-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Overweight and maintains $7 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION